Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention
Schiariti, Michelea,b; Saladini, Angelaa; Cuturello, Domenicob; Missiroli, Bindoa; Puddu, Paolo Emiliob
Free Access
Article Outline
Author Information
aS. Anna Hospital, Catanzaro, Italy
bDepartment of the Heart and Great Vessels ‘A. Reale’, University ‘La Sapienza’, Rome, Italy
Received 28 January, 2010
Revised 22 April, 2010
Accepted 1 June, 2010
Correspondence to P.E. Puddu, MD, FESC, FACC, Dipartimento del Cuore e Grossi Vasi ‘Attilio Reale’, UOC Biotecnologie Applicate alle Malattie Cardiovascolari, Università degli Studi di Roma ‘La Sapienza’, Viale del Policlinico, 155, Rome 00161, Italy Tel: +39 06 4455291; fax: +39 06 4441600; e-mail: [Ссылки доступны только зарегистрированным пользователям ]
Abstract
Background: There is no head-to-head comparison between tirofiban versus eptifibatide in patients undergoing percutaneous coronary intervention (PCI) when added to standard antiaggregating drugs (AAD) to prevent ischemic events within 1 year.
Methods: We compared real-world patients undergoing PCI who were on oral single AAD and were block randomized to receive, immediately preintervention, high-dose tirofiban (n = 519) or double-bolus eptifibatide (n = 147) and a second oral antiplatelet agent. The incidence of composite ischemic events within 1 year, including death, acute myocardial infarction, angina, stent thrombosis or repeat PCI or coronary bypass surgery (primary end-point) was modelled by forced Cox's regression.
Results: There were overall 65 composite ischemic events: 47 (9.1%) in the tirofiban group and 18 (12.2%) in the eptifibatide group (univariate log-rank test: P = 0.22). On the basis of 21 potential covariates fitted simultaneously, multivariable adjusted hazard ratios showed that age [hazard ratio 1.03, 95% confidence interval (CI) 1.01–1.07, P = 0.01], chronic renal failure (hazard ratio 3.21, 95% CI 1.02–10.10, P = 0.05), pre-PCI values of creatine kinase-myocardial band (CK-MB) (hazard ratio 1.002, 95% CI 1.0002–1.0054, P = 0.04), intra-aortic balloon pump (hazard ratio 5.88, 95% CI 12.33–14.85, P = 0.0002) and the presence of eptifibatide (hazard ratio 1.85, 95% CI 1.04–3.29, P = 0.04) were significant risk factors whereas thrombolysis by tenecteplase (hazard ratio 0.19, 95% CI 0.05–0.69, P = 0.01) was a significant protector. Interestingly, eptifibatide versus tirofiban efficacy was explained based on pre-PCI values of CK-MB.
Conclusion: Head-to-head comparison between eptifibatide and tirofiban in patients undergoing PCI while on double AAD showed that eptifibatide had a lower efficacy on the incidence of composite ischemic events within 1 year, which might be explained by a reduced action on CK-MB pre-PCI.
[Ссылки доступны только зарегистрированным пользователям ]